首页> 美国卫生研究院文献>other >Are Central Institutional Review Boards the Solution? The National Heart Lung and Blood Institute Working Groups Report on Optimizing the IRB Process
【2h】

Are Central Institutional Review Boards the Solution? The National Heart Lung and Blood Institute Working Groups Report on Optimizing the IRB Process

机译:是中央机构审查委员会的解决方案?国家心脏肺和血液研究所工作小组的报告对优化IRB过程

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) convened a working group in June 2011 to examine alternative institutional review board (IRB) models. The working group was held in response to proposed changes in the regulations for government-supported research and the proliferation of multicenter clinical trials where multiple individual reviews may be inefficient. Group members included experts in heart, lung, and blood research, research oversight, bioethics, health economics, regulations, and information technology (IT). The group discussed alternative IRB models, ethical concerns, metrics for evaluating IRBs, IT needs, and economic considerations. Participants noted research gaps in IRB best practices and in metrics. The group arrived at recommendations for process changes, such as defining specific IRB performance requirements in funding announcements, requiring funded researchers to use more efficient alternative IRB models, and developing IT systems to facilitate information sharing and collaboration among IRBs. Despite the success of the National Cancer Institute's central IRB (CIRB), the working group, concerned about the creation costs and unknown cost efficiency of a new CIRB, and about the risk of shifting the burden of dealing with multiple IRBs from sponsors to research institutions, did not recommend the creation of an NHLBI-funded CIRB.
机译:美国国立卫生研究院(NIH)的美国国立心肺血液研究所(NHLBI)于2011年6月召集了一个工作组,以研究替代性机构审查委员会(IRB)模型。成立工作组是为了响应政府支持的研究法规的拟议变更以及多中心临床试验激增的情况,在这种情况下,可能需要进行多次个人审查,而效率低下。小组成员包括心脏,肺和血液研究,研究监督,生物伦理学,健康经济学,法规和信息技术(IT)方面的专家。该小组讨论了替代的IRB模型,道德问题,评估IRB的指标,IT需求和经济考虑。与会者指出了IRB最佳做法和指标方面的研究空白。该小组提出了有关流程更改的建议,例如在资助声明中定义特定的IRB性能要求,要求受资助的研究人员使用更有效的IRB替代模型以及开发IT系统以促进IRB之间的信息共享和协作。尽管国家癌症研究所的中央IRB(CIRB)取得了成功,但工作组仍然关注新CIRB的创建成本和未知的成本效率,以及将处理多个IRB的负担从发起人转移到研究机构的风险,不建议创建由NHLBI资助的CIRB。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号